Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report

BACKGROUND: Lung squamous cell cancer (LSCC) rarely harbors epidermal growth factor receptor (EGFR) mutations, even much rarer for acquired T790M mutation. Although clinical trials of AURA series illustrated that non-small cell lung cancer (NSCLC) with EGFR T790M mutation can benefit from osimertini...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Chen, Hui-Min, Liu, Yong-Mei, Peng, Feng, Yu, Min, Wang, Wei-Ya, Xu, Heng, Wang, Yong-Sheng, Lu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547322/
https://www.ncbi.nlm.nih.gov/pubmed/31183356
http://dx.doi.org/10.12998/wjcc.v7.i10.1221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547322/
https://www.ncbi.nlm.nih.gov/pubmed/31183356
http://dx.doi.org/10.12998/wjcc.v7.i10.1221

Ejemplares similares